Vaudry W, Stirling R
NACI Influenza Working Group Chair, University of Alberta, Edmonton, AB.
Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Can Commun Dis Rep. 2017 May 4;43(5):96-103. doi: 10.14745/ccdr.v43i05a03.
Influenza is a respiratory infection caused primarily by influenza A and B viruses. Vaccination is the most effective way to prevent influenza and its complications. The National Advisory Committee on Immunization (NACI) provides recommendations regarding seasonal influenza vaccines annually to the Public Health Agency of Canada (PHAC).
To summarize the NACI recommendations regarding the use of seasonal influenza vaccines for the 2017-2018 influenza season.
Annual influenza vaccine recommendations are developed by NACI's Influenza Working Group for consideration and approval by NACI, based on NACI's evidence-based process for developing recommendations. The recommendations include a consideration of the burden of influenza illness and the target populations for vaccination; efficacy and effectiveness, immunogenicity and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization. These recommendations are published annually on the Agency's website in the NACI Advisory Committee Statement: (the Statement).
The annual statement has been updated for the 2017-2018 influenza season to incorporate recommendations for the use of live attenuated influenza vaccine (LAIV) that were contained in two addenda published after the 2016-2017 statement. These recommendations were 1) that egg-allergic individuals may be vaccinated against influenza using the low ovalbumin-containing LAIV licensed for use in Canada and 2) to continue to recommend the use of LAIV in children and adolescents 2-17 years of age, but to remove the preferential recommendation for its use.
NACI continues to recommend annual influenza vaccination for all individuals aged six months and older, with particular focus on people at high risk of influenza-related complications or hospitalization, people capable of transmitting influenza to those at high risk, and others as indicated.
流感是一种主要由甲型和乙型流感病毒引起的呼吸道感染。接种疫苗是预防流感及其并发症的最有效方法。国家免疫咨询委员会（NACI）每年向加拿大公共卫生署（PHAC）提供有关季节性流感疫苗使用的建议。
总结NACI关于2017 - 2018流感季节使用季节性流感疫苗的建议。
NACI的流感工作组根据NACI制定建议的循证流程制定年度流感疫苗建议，供NACI审议和批准。这些建议包括考虑流感疾病负担和疫苗接种目标人群；流感疫苗的有效性和效果、免疫原性和安全性；疫苗接种时间表；以及流感免疫的其他方面。这些建议每年在该机构网站上以《NACI咨询委员会声明》（声明）的形式发布。
2017 - 2018流感季节的年度声明已更新，纳入了2016 - 2017声明发布后两份增编中包含的关于使用减毒活流感疫苗（LAIV）的建议。这些建议是：1）对鸡蛋过敏的个体可以使用加拿大获批的含低卵清蛋白的LAIV接种流感疫苗；2）继续建议在2至17岁的儿童和青少年中使用LAIV，但取消对其使用的优先推荐。
NACI继续建议所有6个月及以上的个体每年接种流感疫苗，特别关注有流感相关并发症或住院高风险的人群、能够将流感传播给高风险人群的人以及其他指定人群。
